Arsenal Biosciences Presents Four Abstracts at AACR 2024 Highlighting Advancements in Logic-Gated CAR-T Therapies for Solid Tumors
ArsenalBio
Cell Therapy Developer
April 8, 2024 / eMedClub News /--Recently,Arsenal Biosciences in2024 American Association for Cancer Research Annual Meeting（AACR) was announced4 Abstracts. TheseData shows，ArsenalIn understanding and developing logic-gated and integrated circuitsT（ICT）Progress has been made in cell therapy for solid tumorsContinuous Progress. This company once reachedSeptember 2023Well-known industry media Endpoints LaunchYear"Biomedical Most Promising Newcomer"（Biopharma's Most Promising Startups in 2023) List.
AB-1015
AB-1015 is a pipeline in the Phase 1 clinical trial stage at ArsenalBio. Its foundational manufacturing technology involves the precise and specific insertion of large synthetic double-stranded DNA cassettes into a new safe harbor site on chromosome 11 using CRISPR.
The candidate product contains an AND logic gate,The logic gate consists of a priming receptor (PrimeR) and an inducible CAR that can be upregulated by PrimeR., aiming to require the co-expression of two different antigens in ovarian cancer, targeting ALPG/P and MSLN to enhance tumor specificity and safety; it also includes a module for synthetic short hairpin RNA, aiming to modulate gene expression through drugs, thereby enhancing the function of T cells in the tumor microenvironment.
The induction of CAR within the tumor by AB-1015 is a dynamic process influenced by various factors, including antigen density, target cell abundance, and tumor microenvironment factors. The preclinical study results announced this time indicate that the induction of CAR occurs rapidly in response to ALPG activation.Most ICT cells express CAR within 24 hours and reach a peak at 72 hours.Once ALPG is removed, CAR expression recovers to baseline levels within 96 hours. In subsequent studies, it was demonstrated that all PrimeR+ICT cells possess the potential to induce CAR and exhibit robust antitumor activity against ALPG+ and MSLN+ tumors.
AB-2100
AB-2100 is a candidate ICT cell product generated through a CRISPR-mediated single transgene knock-in at a safe harbor site, encoding a transcriptionally regulated AND gate.The gate contains a PrimeR targeting PSMA and an inducible CAR targeting CA9 antigen.Studies have shown that more than 70% of primary and metastatic clear cell renal cell carcinoma (ccRCC) co-express PSMA and CA9. Only when these two targets are present simultaneously can T-cell tumor-killing activity be activated. Additionally, AB-2100 includes short hairpin RNAs (shRNAs) targeting Fas and TGFBR, aiming to enhance tumor-killing activity and reduce drug resistance.
The results of this study show that AB-2100 can specifically kill tumor cells and overcome various inhibitory mechanisms in the tumor microenvironment, supporting its clinical use for the treatment of ccRCC. Currently, AB-2100 is in phase 1/2 clinical trials.
The other two abstracts from ArsenalBio are about sequencing and CRISPR technology, which are used to explore factors influencing the function of CAR-T/TCR-T cells to enhance their therapeutic efficacy in solid tumors.
Arsenal Technology Platform and Pipeline
eMedClub
ArsenalBio is a company focused on programmable cell therapy, dedicated to integrating technologies such as CRISPR-based genome engineering, synthetic biology, and machine learning to advance the development of immune cell therapies. Currently, the company has established multiple technology platforms, including a programmable T-cell platform, CITR platform, synthetic technology platform, and logic-gated platform.
CITE Technology Platform
ArsenalBio's synthetic biology modules are all based on a highly specific CRISPR method—CITE, which is mediated by electroporation to deliver encoded DNA into the T-cell genome and insert it at specific sites.CITE minimizes the risk of insertional mutagenesis inherent in viral vectors., and maximizes the potential payload that can be inserted into the T-cell genome.
During the preparation process, the generated memory phenotype T cells can effectively delay T cell exhaustion until they reach the tumor site, and are expected to shorten the waiting time for patients to receive treatment.
Synthetic Technology Platform
ArsenalBio is developing enhanced CAR-T cell therapies by creating new synthetic modules and integrating them into T cells, endowing CAR-T cells with new functionalities. With the development of each candidate product, ArsenalBio adds extra modules with the goal of providing greater anti-tumor benefits to patients by enhancing potency, evading the suppressive tumor microenvironment, and delaying T-cell exhaustion.
Logic Gate-Controlled Platform
ArsenalBio primarily develops AND gates, which activate T cells only when two signals are triggered at the tumor site. This approach kills tumor cells without affecting healthy ones. Additionally, the triggering conditions of the logic gates can be "customized" to create more precise cell therapies for treating a wider range of tumor types.
Based on these technology platforms, ArsenalBio has developed multiple R&D pipelines. In addition to the aforementioned AB-1015 and AB-2100, which have already entered clinical trials, there are four other candidate pipelines at the preclinical stage. Among them, AB-3000 is ArsenalBio’s project targeting prostate cancer, also utilizing a logic-gated approach, with the target replaced by specific antigens found in prostate cancer patient tumors. Compared to AB-2100, AB-3000 incorporates a modification that further enhances anti-tumor activity and stimulates additional anti-tumor immunity within the patient's body.
The other three pipelines are co-developed with BMS and Genentech, respectively. The disclosed AB-4000 and AB-5000, which are in collaboration with BMS, both target solid tumors.
Summary
eMedClub
ArsenalBio, as one of the leaders in the synthetic biology and cell therapy赛道, has already achieved numerous research results and gained recognition. Its logic-gated cell therapy product has entered the clinical trial stage, and it is expected that more clinical data will be released in the future to support the safety and efficacy of logic-gated cell therapy.
Logic-gated design can enhance the specificity of cell therapy in tumors, reduce off-target effects, and theoretically program cells, offering numerous potential advantages. However, there are still some challenges in current applications.
The design of logic-gated CAR-T cell therapy is complex, requiring precise regulation of CAR-T cell activity, and precisely designing gene expression during the development process remains a challenge. Additionally, ensuring the maximum activation of logic-gated CAR-T cells in vivo is critical, as low activation rates may lead to suboptimal efficacy. Moreover, the preparation process of logic-gated CAR-T cell therapy is complicated, so how to ensure that the cells' viability and functionality remain unaffected during manufacturing?
eMedclub
References:
1、Official Websites and Official WeChat Accounts of Various Companies
